Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling

Journal of Immunology

Volumn 185, Issue 2, 2010, Pages 1103-1113

  Ahmed, Chulbul M I ^a   Dabelic, Rea ^a   Martin, James P ^a   Jager, Lindsey D ^a   Haider, S Mohammad ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON; JANUS KINASE 2; JANUS KINASE 2(1001-1013); NEUTRALIZING ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN INHIBITOR; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; PEPTIDE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; ENZYME ACTIVATION; MOUSE; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNITY; IMMUNOLOGY; KAPLAN MEIER METHOD; L CELL; METABOLISM; MOLECULAR GENETICS; PICORNAVIRUS INFECTION; VACCINIA; VIROLOGY; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; FEMALE; HUMANS; IMMUNITY; INTERFERON-BETA; INTERFERON-GAMMA; JANUS KINASE 2; KAPLAN-MEIERS ESTIMATE; L CELLS (CELL LINE); MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; PEPTIDES; PICORNAVIRIDAE; PICORNAVIRIDAE INFECTIONS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; VACCINIA; VACCINIA VIRUS;

EID: 77955484240     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902895     Document Type: Article

References (46)

1. Moss, B. 2007. Poxviridae. In Fields Virology, 3rd Ed. D. M. Knipe, and P. M. Howley, eds. Lippincott, Williams, and Wilkins, Philadelphia, PA, pp. 2905-2945.
2. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3: 201-213.
3. Smith, G. L., and G. McFadden. 2002. Smallpox: anything to declare? Nat. Rev. Immunol. 2: 521-527.
4. Moss, B., and J. L. Shisler. 2001. Immunology 101 at poxvirus U: immune evasion genes. Semin. Immunol. 13: 59-66.
5. Alcamí, A., and G. L. Smith. 2002. The vaccinia virus soluble interferon-gamma receptor is a homodimer. J. Gen. Virol. 83: 545-549.
6. Racaniello, V. R. 2007. Picornaviridae: The viruses and their replication. In Fields Virology, 3rd Ed. D. M. Knipe, and P. M. Howley, eds. Lippincott, Williams, and Wilkins, Philadelphia, PA, pp. 795-838.
7. Rose, N. R. 2000. Viral damage or 'molecular mimicry'-placing the blame in myocarditis. Nat. Med. 6: 631-632.
8. Yajima, T., and K. U. Knowlton. 2009. Viral myocarditis: from the perspective of the virus. Circulation 119: 2615-2624.
9. Mujtaba, M. G., C. B. Patel, R. A. Patel, L. O. Flowers, M. A. Burkhart, L. W. Waiboci, J. P. Martin, M. I. Haider, C. M. Ahmed, and H. M. Johnson. 2006. The gamma interferon (IFN-gamma) mimetic peptide IFN-gamma (95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice. Clin. Vaccine Immunol. 13: 944-952.
10. Ahmed, C. M., M. A. Burkhart, P. S. Subramaniam, M. G. Mujtaba, and H. M. Johnson. 2005. Peptide mimetics of gamma interferon possess antiviral properties against vaccinia virus and other viruses in the presence of poxvirus B8R protein. J. Virol. 79: 5632-5639.
11. Ahmed, C. M., J. P. Martin, and H. M. Johnson. 2007. IFN mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses. J. Immunol. 178: 4576-4583.
12. Frey, K. G., C. M. Ahmed, R. Dabelic, L. D. Jager, E. N. Noon-Song, S. M. Haider, H. M. Johnson, and N. J. Bigley. 2009. HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion. J. Immunol. 183: 1253-1262.
13. Roizman, B. D., M. Knipe, and R. J. Whitley. 2007. Herpes Simplex Viruses. In Fields Virology, 3rd Ed. D. M. Knipe, and P. M. Howley, eds. Lippincott, Williams, and Wilkins, Philadelphia, PA, pp. 2501-2602.
14. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7: 454-465.
15. Mansell, A., R. Smith, S. L. Doyle, P. Gray, J. E. Fenner, P. J. Crack, S. E. Nicholson, D. J. Hilton, L. A. O'Neill, and P. J. Hertzog. 2006. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7: 148-155.
16. Yasukawa, H., H. Misawa, H. Sakamoto, M. Masuhara, A. Sasaki, T. Wakioka, S. Ohtsuka, T. Imaizumi, T. Matsuda, J. N. Ihle, and A. Yoshimura. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18: 1309-1320. (Pubitemid 29110315)
17. Kobayashi, T., G. Takaesu, and A. Yoshimura. 2006. Mal-function of TLRs by SOCS. Nat. Immunol. 7: 123-124.
18. Croker, B. A., H. Kiu, and S. E. Nicholson. 2008. SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19: 414-422.
19. Waiboci, L. W., C. M. Ahmed, M. G. Mujtaba, L. O. Flowers, J. P. Martin, M. I. Haider, and H. M. Johnson. 2007. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J. Immunol. 178: 5058-5068.
20. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses: interferon-alpha/β revisited. Nat. Rev. Mol. Cell Biol. 2: 378-386.
21. Takaoka, A., Y. Mitani, H. Suemori, M. Sato, T. Yokochi, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Cross talk between interferon-γ and -α/β signaling components in caveolar membrane domains. Science 288: 2357-2360. (Pubitemid 30448158)
22. Chen, H. M., N. Tanaka, Y. Mitani, E. Oda, H. Nozawa, J. Z. Chen, H. Yanai, H. Negishi, M. K. Choi, T. Iwasaki, et al. 2009. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci. 100: 449-456.
23. Szente, B. E., J. M. Soos, and H. W. Johnson. 1994. The C-terminus of IFN gamma is sufficient for intracellular function. Biochem. Biophys. Res. Commun. 203: 1645-1654.
24. Ahmed, C. M., M. A. Burkhart, M. G. Mujtaba, P. S. Subramaniam, and H. M. Johnson. 2003. The role of IFNgamma nuclear localization sequence in intracellular function. J. Cell Sci. 116: 3089-3098.
25. Ahmed, C. M., and H. M. Johnson. 2006. IFN-gamma and its receptor subunit IFNGR1 are recruited to the IFN-gamma-activated sequence element at the promoter site of IFN-gamma-activated genes: evidence of transactivational activity in IFNGR1. J. Immunol. 177: 315-321.
26. Fulcher, A. J., C. M. Ahmed, E. N. Noon-Song, R. Y. Q. Kwan, P. S. Subramaniam, H. M. Johnson, and D. A. Jans. 2008. Interferon γ is recognised by importin α/β: enhanced nuclear localising and transactivation activities of an interferon γ mimetic. FEBS Lett. 582: 1569-1574.
27. Fleischmann, W. R., Jr., J. A. Georgiades, L. C. Osborne, and H. M. Johnson. 1979. Potentiation of interferon activity by mixed preparations of fibroblast and immune interferon. Infect. Immun. 26: 248-253.
28. Song, X. T., K. Evel-Kabler, L. Rollins, M. Aldrich, F. Gao, X. F. Huang, and S. Y. Chen. 2006. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 3: e11.
29. Shen, L., K. Evel-Kabler, R. Strube, and S. Y. Chen. 2004. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22: 1546-1553.
30. Torres, B. A., G. Q. Perrin, M. G. Mujtaba, P. S. Subramaniam, A. K. Anderson, and H. M. Johnson. 2002. Superantigen enhancement of specific immunity: antibody production and signaling pathways. J. Immunol. 169: 2907-2914.
31. Matsumoto, M., and T. Seya. 2008. TLR3: interferon induction by doublestranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60: 805-812.
32. Vercammen, E., J. Staal, and R. Beyaert. 2008. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin. Microbiol. Rev. 21: 13-25.
33. Pothlichet, J., M. Chignard, and M. Si-Tahar. 2008. Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. J. Immunol. 180: 2034-2038.
34. Ahmed, C. M. I., K. N. Wills, B. J. Sugarman, D. E. Johnson, M. Ramachandra, T. L. Nagabhushan, and J. A. Howe. 2001. Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice. J. Interferon Cytokine Res. 21: 399-408.
35. Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B. Zhu, C. Tato, A. Yoshimura, L. Henninghausen, and J. J. O'Shea. J.J. 2006. Selective regulatory function of Socs3 in the formation of IL-17-secreting cells. Proc. Natl. Acad. Sci. USA 103: 8137-8142.
36. Marine, J. C., D. J. Topham, C. McKay, D. Wang, E. Parganas, D. Stravopodis, A. Yoshimura, J. N. Ihle, and J. N. Ihle. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98: 609-616.
37. Brysha, M., J. G. Zhang, P. Bertolino, J. E. Corbin, W. S. Alexander, N. A. Nicola, D. J. Hilton, and R. Starr. 2001. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J. Biol. Chem. 276: 22086-22089.
38. Metcalf, D., W. S. Alexander, A. G. Elefanty, N. A. Nicola, D. J. Hilton, R. Starr, S. Mifsud, and L. Di Rago. 1999. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13: 926-934. (Pubitemid 29292144)
39. Zimmerer, J. M., G. B. Lesinski, S. V. Kondadasula, V. I. Karpa, A. Lehman, A. Raychaudhury, B. Becknell, and W. E. Carson, 3rd. 2007. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins. J. Immunol. 178: 4832-4845.
40. Zhang, J. G., A. Farley, S. E. Nicholson, T. A. Wilson, L. M. Zugaro, R. J. Simpson, R. L. Mortiz, D. Cary, R. Richardson, G. Hausman, et al. 1999. The conserved SOCs box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96: 2071-2076.
41. Yasukawa, H., T. Yajima, H. Duplain, M. Iwatate, M. Kido, M. Hoshijima, M. D. Weitzman, T. Nakamura, S. Woodard, D. Xiong, et al. 2003. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111: 469-478.
42. Johnson, H. M., and C. M. Ahmed. 2006. Gamma interferon signaling: insights to development of interferon mimetics. Cell Mol Biol (Noisy-le-grand) 52: 71-76.
43. Lo, H. W., S. C. Hsu, and M. C. Hung. 2006. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 95: 211-218.
44. Shin-Ya, M., H. Hirai, E. Satoh, T. Kishida, H. Asada, F. Aoki, M. Tsukamoto, J. Imanishi, and O. Mazda. 2005. Intracellular interferon triggers Jak/Stat signaling cascade and induces p53-dependent antiviral protection. Biochem. Biophys. Res. Commun. 329: 1139-1146.
45. Subramaniam, P. S., and H. M. Johnson. 2004. The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence. FEBS Lett. 578: 207-210.
46. Wagstaff, K. M., and D. A. Jans. 2009. Importins and beyond: non-conventional nuclear transport mechanisms. Traffic 10: 1188-1198.